Herbst RS - Search Results

1

Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.

Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, Bucana CD, Pathak S, Kruzel E, Herbst RS, Onn A, Roach JS, Onda M, Wang QC, Pastan I, Fidler IJ. Fan D, et al. Among authors: herbst rs. Mol Cancer Ther. 2002 Jun;1(8):595-600. Mol Cancer Ther. 2002. PMID: 12479219

2

Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.

Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Herbst RS, et al. Clin Cancer Res. 2000 Mar;6(3):790-7. Clin Cancer Res. 2000. PMID: 10741698

3

Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.

Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Yano S, et al. Among authors: herbst rs. Clin Cancer Res. 2000 Mar;6(3):957-65. Clin Cancer Res. 2000. PMID: 10741721

4

Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis.

Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Davis DW, McConkey DJ, Fidler IJ. Yano S, et al. Among authors: herbst rs. Cancer Res. 2000 Sep 1;60(17):4959-67. Cancer Res. 2000. PMID: 10987313

5

Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

Yano S, Shinohara H, Herbst RS, Kuniyasu H, Bucana CD, Ellis LM, Fidler IJ. Yano S, et al. Among authors: herbst rs. Am J Pathol. 2000 Dec;157(6):1893-903. doi: 10.1016/S0002-9440(10)64828-6. Am J Pathol. 2000. PMID: 11106562 Free PMC article.

6

Angiogenesis and lung cancer: potential for therapy.

Herbst RS, Fidler IJ. Herbst RS, et al. Clin Cancer Res. 2000 Dec;6(12):4604-6. Clin Cancer Res. 2000. PMID: 11156208 Review. No abstract available.

7

Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy.

Onn A, Tseng JE, Herbst RS. Onn A, et al. Among authors: herbst rs. Clin Cancer Res. 2001 Nov;7(11):3311-3. Clin Cancer Res. 2001. PMID: 11705841 No abstract available.

8

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.

Tseng JE, Glisson BS, Khuri FR, Shin DM, Myers JN, El-Naggar AK, Roach JS, Ginsberg LE, Thall PF, Wang X, Teddy S, Lawhorn KN, Zentgraf RE, Steinhaus GD, Pluda JM, Abbruzzese JL, Hong WK, Herbst RS. Tseng JE, et al. Among authors: herbst rs. Cancer. 2001 Nov 1;92(9):2364-73. doi: 10.1002/1097-0142(20011101)92:9<2364::aid-cncr1584>3.0.co;2-p. Cancer. 2001. PMID: 11745292 Clinical Trial.

9

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy.

Herbst RS, Shin DM. Herbst RS, et al. Cancer. 2002 Mar 1;94(5):1593-611. doi: 10.1002/cncr.10372. Cancer. 2002. PMID: 11920518 Free article.

10

The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.

Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G Jr, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. Herbst RS, et al. Cancer. 2002 Jul 15;95(2):340-53. doi: 10.1002/cncr.10629. Cancer. 2002. PMID: 12124835 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

427 results

Search Page